Xinyan Li, Ph.D., joined Frontera Therapeutics in October 2020 as the President, leading the Clinical Department responsibility for the Clinical Operations, Medical Affairs, Biometrics, Registration and Marketing. Dr. Li worked 5 years as an internal medicine doctor and 10 years teaching in medical school and conducting scientific research, before starting her journey in drug development as an oversees returnee. Ever since Dr.Li has been engaged in innovative drug R&D management for 20 years, including R&D, preclinical efficacy/safety evaluation, clinical Trials, registration, drug production and quality control (QC and QA), government relations, fund applications, etc.
As the project leader, Dr. Li successfully led the development of two innovative drugs in China and U.S., and gained valuable management experience in the field of innovative drug R&D. At Carsgen, Dr. Li presided over the pre-clinical, IIT, registered clinical research, and China and US registration of CART cell products.
As the principal investigator, Dr. Li also led a series of National Significant New Drugs Development Projects during the Eleventh, Twelfth, and Thirteenth Five-year Plan Periods.
Dr. Li received a B.S. in immunology and Ph. D. in Internal Medicine from the Soochow University, and was a visiting scholar at the Gene and Cell Therapy Center of the University of Montpellier, France.